DarioHealth Corp
Company Profile
Business description
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Contact
322 West 57th Street
New YorkNY10019
USAT: +1 972 770-6377
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
165
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
stocks
Our top ASX picks in every sector
stocks
Which of the 3 giant AI IPOs should you buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.80 | 27.10 | 0.30% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 54,067.01 | 327.33 | 0.61% |
| NZX 50 Index | 12,960.42 | 134.55 | 1.05% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,717.60 | 32.60 | 0.38% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |